Three of the five drugs have a high chance of being on the list of new therapeutics against the coronavirus by October 2021
The European Commission has announced a portfolio of the first five potential drugs to treat COVID-19, which could soon be available to treat patients across the EU.
A statement to that effect was published on the EC’s website.
“Five products are in an advanced stage of development and have high potential to be among the three new therapeutics against COVID-19 that will receive approval by October 2021,” the statement reads.
Four of the five promising drugs are monoclonal antibodies that are now undergoing ongoing review by the European Medicines Agency (EMA). Another one is already in use as an immunosuppressant, whose marketing authorization could also be extended to treat patients with COVID-19.
We are taking the first step today towards building a broad portfolio of therapeutics to treat COVID-19,” said EU Health and Food Safety Commissioner Stella Kyriakidis.
She also noted that despite progress in vaccination, the virus is not going away, so a safe and effective treatment for COVID-19 is needed.
Potential medications for COVID-19:
— The immunosuppressant baricitinib (a drug that reduces immune system activity) from Eli Lilly.
— A combination of bamlanivimab and etesivimab from Eli Lilly.
— Combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd.
— Regganivimab by Celltrion.
— Sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.
It is noted that three of these five drugs have a high chance of being among the three new therapeutics against COVID-19 that will receive approval by October 2021.